Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer

• Published in: Cancer medicine (Malden, MA) MA), 2022-03, Vol.11 (6), p.1474-1483
• Main Authors: Layman, Rachel M., Lin, Heather, Gutierrez Barrera, Angelica M., Karuturi, Meghan S., Yam, Clinton, Arun, Banu K.
• Format: Article
• Language: English
• Subjects: BRCA1; BRCA1 protein; BRCA2; BRCA2 protein; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - therapy; Chemotherapy; Chemotherapy, Adjuvant; Clinical Cancer Research; Clinical outcomes; Clinical trials; Endocrine therapy; ErbB-2 protein; estrogen receptor; Estrogen receptors; Family medical history; Female; gene expression profiling; Genetic analysis; Genetic screening; Humans; Invasiveness; Multivariate analysis; Mutation; Neoplasm Recurrence, Local - pathology; Ovarian cancer; Patients; Progesterone; Radiation therapy; Survival; survival analysis
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.4566

Background BRCA‐associated breast cancers tend to have distinctive features compared to sporadic breast cancers; further characterization can aid in optimizing treatment. Methods The study evaluated a patient cohort with early‐stage estrogen receptor positive, HER2 negative invasive breast cancer who had Oncotype DX Breast Recurrence Score® analysis and genetic testing for hereditary breast and ovarian cancer syndrome. Data on patients and their breast cancers with outcomes were collected and analyzed. Results 745 patients were included, of whom 33 had pathogenic BRCA mutations (8 BRCA1, 25 BRCA2). Patients with BRCA mutations were younger and received more adjuvant chemotherapy, but less endocrine therapy and radiation therapy. BRCA‐associated breast cancers had less progesterone receptor expression, higher nuclear grade, and higher Oncotype DX Breast Recurrence Scores® with median Recurrence Score® 29, compared to 16 in cancers without mutations (p